Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

SOLUTIONS

RESOURCES

ABOUT US

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  San Francisco
US -  Boston

GLOBAL

English

Novotech Partners with South Korea’s 800,000-patient Kyung Hee University Hospital at Gangdong for Biotech Clinical Trials

Novotech Partners with South Korea’s 800,000-patient Kyung Hee University Hospital at Gangdong for Biotech Clinical Trials

July 27,2020

The leading Asia-Pacific biotech specialist CRO Novotech has partnered with South Korea’s 800-bed Kyung Hee University Hospital at Gangdong, Seoul.

The hospital is an ideal clinical trials partner for Novotech with its 800 beds, 403 investigators (as of July 2020) with 835,905 outpatients and 207,956 inpatients per year, and 14,726 surgeries in 2019.

The Partnership is designed to further support Novotech’s biotech clients run their clinical trials in the region.

Dr. Ki Tack KIM, President from Kyung Hee University Hospital at Gangdong said:

 “We are pleased to be partnering with a regional CRO leader with such an outstanding reputation internationally. The hospital is well positioned to further support Novotech’s biotech clients from around the globe.”

Dr. Yooni Kim, Executive Director, Asia Operations said:

“Novotech is pleased to have a valued Partnership agreement with Kyung Hee University Hospital at Gangdong which has completed more than 300 clinical trials (GlobalData).

“The hospital offers biotechs quality infrastructure, world-class medical and hospital facilities, as well as South Korea’s supportive rapid start-up environment. South Korea is the most active country in clinical research in Asia after China,” she said.

Novotech now has over 30 significant Partnerships with some of the leading medical institutions in the region. The Partnership Program is strategically designed to deliver unparalleled access to quality investigators, KOLs, and up to 4 million patients for its international biotech clients.